Interpreting disparate responses to cancer therapy: The role of human population genetics

Journal of Clinical Oncology

Volumn 24, Issue 14, 2006, Pages 2151-2157

  Maitland, Michael L ^a   DiRienzo, Anna ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; INTRINSIC FACTOR; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

CANCER INCIDENCE; CANCER THERAPY; DRUG EFFICACY; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHARMACOGENOMICS; POPULATION GENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; TREATMENT OUTCOME; GENETIC VARIABILITY; GENETICS; NEOPLASM; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; GENETICS, POPULATION; HUMANS; NEOPLASMS; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 33646564372     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.2282     Document Type: Review

References (75)

1. Desai AA, Innocenti F, Ratain MJ: Pharmacogenomics: Road to anticancer therapeutics nirvana? Oncogene 22:6621-6628, 2003
2. Relling MV, Dervieux T: Pharmacogenetics and cancer therapy. Nat Rev Cancer 1:99-108, 2001
3. Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials. Washignton, DC, Food and Drug Administration Center for Drug Evaluation and Research, US Department of Health and Human Services, 2005
4. Oppenheimer GM: Paradigm lost: Race, ethnicity, and the search for a new population taxonomy. Am J Public Health 91:1049-1055, 2001
5. Schwartsmann G, Ratain MJ, Cragg GM, et al: Anticancer drug discovery and development throughout the world. J Clin Oncol 20:47S-59S, 2002
6. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003
7. Hanna NH, Einhorn L, Sandler A, et al: Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. J Clin Oncol 23:1094s, 2005 (suppl; abstr 7004)
8. Hinds DA, Stuve LL, Nilsen GB, et al: Whole-genome patterns of common DNA variation in three human populations. Science 307:1072-1079, 2005
9. Altshuler D, Brooks LD, Chakravarti A, et al: A haplotype map of the human genome. Nature 437: 1299-1320, 2005
10. Rosenberg NA, Pritchard JK, Weber JL, et al: Genetic structure of human populations. Science 298:2381-2385, 2002
11. Serre D, Paabo S: Evidence for gradients of human genetic diversity within and among continents. Genome Res 14:1679-1685, 2004
12. Tishkoff SA, Kidd KK: Implications of biogeography of human populations for 'race' and medicine. Nat Genet 36:S21-S27, 2004
13. Race, Ethnicity, an Genetics Working Group: The use of racial, ethnic, and ancestral categories in human genetics research. Am J Hum Genet 77:519-532, 2005
14. Burchard EG, Ziv E, Coyle N, et al: The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348: 1170-1175, 2003
15. Chakravarti A, Little P: Nature, nurture and human disease. Nature 421:412-414, 2003
16. Cooper RS, Kaufman JS, Ward R: Race and genomics. N Engl J Med 348:1166-1170, 2003
17. Goldstein DB, Hirschhorn JN: In genetic control of disease, does 'race' matter? Nat Genet 36: 1243-1244, 2004
18. Kaplan JB, Bennett T: Use of race and ethnicity in biomedical publication. JAMA 289:2709-2716, 2003
19. Risch N, Burchard E, Ziv E, et al: Categorization of humans in biomedical research: Genes, race and disease. Genome Biol 3:comment2007, 2002
20. Sankar P, Cho MK: Genetics: Toward a new vocabulary of human genetic variation. Science 298: 1337-1338, 2002
21. Chakravarti A: To a future of genetic medicine. Nature 409:822-823, 2001
22. Sachidanandam R, Weissman D, Schmidt SC, et al: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933, 2001
23. Kaessmann H, Wiebe V, Paabo S: Extensive nuclear DNA sequence diversity among chimpanzees. Science 286:1159-1162, 1999
24. Fischer A, Wiebe V, Paabo S, et al: Evidence for a complex demographic history of chimpanzees. Mol Biol Evol 21:799-808, 2004
25. Jorde LB, Watkins WS, Bamshad MJ: Population genomics: A bridge from evolutionary history to genetic medicine. Hum Mol Genet 10:2199-2207, 2001
26. Kittles RA, Weiss KM: Race, ancestry, and genes: Implications for defining disease risk. Annu Rev Genomics Hum Genet 4:33-67, 2003
27. Tishkoff SA, Verrelli BC: Patterns of human genetic diversity: Implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 4:293-340, 2003
28. Harpending H, Rogers A: Genetic perspectives on human origins and differentiation. Annu Rev Genomics Hum Genet 1:361-385, 2000
29. Kimura M: Evolutionary rate at the molecular level. Nature 217:624-626, 1968
30. King JL, Jukes TH: Non-Darwinian evolution. Science 164:788-798, 1969
31. Aquadro CF, Bauer DuMont V, Reed FA: Genome-wide variation in the human and fruitfly: A comparison. Curr Opin Genet Dev 11:627-634, 2001
32. Hey J: The neutralist, the fly and the selectionist. Trends Ecol Evol 14:35-38, 1999
33. Tishkoff SA, Varkonyi R, Cahinhinan N, et al: Haplotype diversity and linkage disequilibrium at human G6PD: Recent origin of alleles that confer malarial resistance. Science 293:455-462, 2001
34. Hamblin MT, Thompson EE, Di Rienzo A: Complex signatures of natural selection at the Duffy blood group locus. Am J Hum Genet 70:369-383, 2002
35. Kreitman M: Methods to detect selection in populations with applications to the human. Annu Rev Genomics Hum Genet 1:539-559, 2000
36. Akey JM, Eberle MA, Rieder MJ, et al: Population history and natural selection shape patterns of genetic variation in 132 genes. PLoS Biol 2:e286, 2004
37. Akey JM, Zhang G, Zhang K, et al: Interrogating a high-density SNP map for signatures of natural selection. Genome Res 12:1805-1814, 2002
38. Cavalli-Sforza LL, Menozzi P, Piazza A: The history and Geography of Human Genes. Princeton, NJ, Princeton University Press, 1994
39. Livingstone F: On the non-existence of human races. Current Anthropology 3:279-281, 1962
40. Lewontin RC: The apportionment of human diversity, in Dobzhansky T, Hecht MK, Steere WC (eds): Evolutionary Biology. New York, NY, Appleton-Century- Crofts, 1972, pp 381-398
41. Bamshad MJ, Wooding S, Watkins WS, et al: Human population genetic structure and inference of group membership. Am J Hum Genet 72:578-589, 2003
42. Bamshad M, Wooding S, Salisbury BA, et al: Deconstructing the relationship between genetics and race. Nat Rev Genet 5:598-609, 2004
43. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: Past successes for Mendelian disease, future approaches for complex disease. Nat Genet 33:228-237, 2003 (suppl)
44. Pritchard JK: Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 69:124-137, 2001
45. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet 17:502-510, 2001
46. Cohen JC, Kiss RS, Pertsemlidis A, et al: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869-872, 2004
47. Goldstein DB, Tate SK, Sisodiya SM: Pharmacogenetics goes genomic. Nat Rev Genet 4:937-947, 2003
48. Nebert DW, Vesell ES: Advances in pharmacogenomics and individualized drug therapy: Exciting challenges that lie ahead. Eur J Pharmacol 500:267-280, 2004
49. Nebert DW: Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist? Am J Hum Genet 60:265-271, 1997
50. Tate SK, Goldstein DB: Will tomorrow's medicines work for everyone? Nat Genet 36:S34-S42, 2004
51. Wooding SP, Watkins WS, Bamshad MJ, et al: DNA sequence variation in a 3.7-kb noncoding sequence 5′ of the CYP1A2 gene: Implications for human population history and natural selection. Am J Hum Genet 71:528-542, 2002
52. Oota H, Pakstis AJ, Bonne-Tamir B, et al: The evolution and population genetics of the ALDH2 locus: Random genetic drift, selection, and low levels of recombination. Ann Hum Genet 68:93-109, 2004
53. Osier MV, Pakstis AJ, Soodyall H, et al: A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet 71:84-99, 2002
54. Bersaglieri T, Sabeti PC, Patterson N, et al: Genetic signatures of strong recent positive selection at the lactase gene. Am J Hum Genet 74:1111-1120, 2004
55. Campbell CD, Ogburn EL, Lunetta KL, et al: Demonstrating stratification in a European American population. Nat Genet 37:868-872, 2005
56. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
57. Balram C, Sabapathy K, Fei G, et al: Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12:81-83, 2002
58. Hall D, Ybazeta G, Destro-Bisol G, et al: Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9:591-599, 1999
59. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
60. Sai K, Saeki M, Saito Y, et al: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515, 2004
61. Maitland ML, Grimsley C, Kuttab-Boulos H, et al: Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J 6:52-62, 2006
62. Innocenti F, Grimsley C, Das S, et al: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733, 2002
63. Wilson JF, Weale ME, Smith AC, et al: Population genetic structure of variable drug response. Nat Genet 29:265-269, 2001
64. Rotimi CN: Are medical and nonmedical uses of large-scale genomic markers conflating genetics and 'race'? Nat Genet 36:S43-S47, 2004
65. Foster MW, Sharp RR: Race, ethnicity, and genomics: Social classifications as proxies of biological heterogeneity. Genome Res 12:844-850, 2002
66. Mountain JL, Risch N: Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nat Genet 36:S48-S53, 2004
67. Stellman SD, Resnicow K: Tobacco smoking, cancer and social class, in Kogivenas M, Pearce N, Susser M, et al (eds): Social Inequalities and Cancer. Lyon, France, IARC Scientific Publication No. 138, 1997, pp 229-250
68. Moller H, Tonnesen H: Alcohol drinking, social class and cancer, in Kogivenas M, Pearce N, Susser M, et al (eds): Social Inequalities and Cancer. Lyon, France, IARC Scientific Publication No. 138, 1997, pp 251-263
69. Polite BN, Dignam JJ: Colorectal cancer model of health disparities: Understanding mortality differences in minority populations. J Clin Oncol 24:2179-2189, 2006
70. Anderson K, Conney A, Kappas A: Nutrition as an environmental influence on chemical metabolism in man, in Kalow W, Goedde H, Agarwal D (eds): Ethnic Differences in Reactions to Drugs and Xenobiotics. New York, NY, Alan R. Liss Inc, 1986, pp 39-54
71. Dollery CT, Fraser HS, Mucklow JC, et al: Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev 9:207-220, 1979
72. Axelson ML: The impact of culture on food-related behavior. Annu Rev Nutr 6:345-363, 1986
73. Shatenstein B, Ghadirian P: Influences on diet, health behaviours and their outcome in select ethnocultural and religious groups. Nutrition 14:223-230, 1998
74. Kolonel LN, Altshuler D, Henderson BE: The multiethnic cohort study: Exploring genes, lifestyle and cancer risk. Nat Rev Cancer 4:519-527, 2004
75. Scully C, Bedi R: Ethnicity and oral cancer. Lancet Oncol 1:37-42, 2000